192 related articles for article (PubMed ID: 20851099)
1. Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid.
Khumsupan P; Ramirez R; Khumsupan D; Narayanaswami V
Biochim Biophys Acta; 2011 Jan; 1808(1):352-9. PubMed ID: 20851099
[TBL] [Abstract][Full Text] [Related]
2. Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing reconstituted HDL as a nanovehicle.
Kim SH; Adhikari BB; Cruz S; Schramm MP; Vinson JA; Narayanaswami V
PLoS One; 2015; 10(8):e0135130. PubMed ID: 26258481
[TBL] [Abstract][Full Text] [Related]
3. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain.
Redmond KA; Murphy C; Narayanaswami V; Kiss RS; Hauser P; Guigard E; Kay CM; Ryan RO
FEBS J; 2006 Feb; 273(3):558-67. PubMed ID: 16420479
[TBL] [Abstract][Full Text] [Related]
4. The LDL receptor binding domain of apolipoprotein E directs the relative orientation of its C-terminal segment in reconstituted nascent HDL.
Kothari S; Bala N; Patel AB; Donovan A; Narayanaswami V
Biochim Biophys Acta Biomembr; 2021 Jul; 1863(7):183618. PubMed ID: 33831404
[TBL] [Abstract][Full Text] [Related]
5. Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particles.
Narayanaswami V; Maiorano JN; Dhanasekaran P; Ryan RO; Phillips MC; Lund-Katz S; Davidson WS
J Biol Chem; 2004 Apr; 279(14):14273-9. PubMed ID: 14739281
[TBL] [Abstract][Full Text] [Related]
6. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
7. High density lipoprotein structure-function and role in reverse cholesterol transport.
Lund-Katz S; Phillips MC
Subcell Biochem; 2010; 51():183-227. PubMed ID: 20213545
[TBL] [Abstract][Full Text] [Related]
8. Anionic phospholipids inhibit apolipoprotein E--low-density lipoprotein receptor interactions.
Yamamoto T; Ryan RO
Biochem Biophys Res Commun; 2007 Mar; 354(3):820-4. PubMed ID: 17258176
[TBL] [Abstract][Full Text] [Related]
9. Ordered opening of LDL receptor binding domain of human apolipoprotein E3 revealed by hydrogen/deuterium exchange mass spectrometry and fluorescence spectroscopy.
Yang L; Hernandez RV; Tran TN; Nirudodhi S; Beck WHJ; Maier CS; Narayanaswami V
Biochim Biophys Acta Proteins Proteom; 2018 Nov; 1866(11):1165-1173. PubMed ID: 30282614
[TBL] [Abstract][Full Text] [Related]
10. Role of leucine zipper motif in apoE3 N-terminal domain lipid binding activity.
Yamamoto T; Ryan RO
Biochim Biophys Acta; 2006 Sep; 1761(9):1100-6. PubMed ID: 16945585
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3.
Weers PM; Narayanaswami V; Ryan RO
Eur J Biochem; 2001 Jul; 268(13):3728-35. PubMed ID: 11432739
[TBL] [Abstract][Full Text] [Related]
12. Orientation and mode of lipid-binding interaction of human apolipoprotein E C-terminal domain.
Raussens V; Drury J; Forte TM; Choy N; Goormaghtigh E; Ruysschaert JM; Narayanaswami V
Biochem J; 2005 May; 387(Pt 3):747-54. PubMed ID: 15588256
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183).
Raussens V; Mah MK; Kay CM; Sykes BD; Ryan RO
J Biol Chem; 2000 Dec; 275(49):38329-36. PubMed ID: 10986285
[TBL] [Abstract][Full Text] [Related]
14. Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice.
Kawashiri M; Zhang Y; Usher D; Reilly M; Puré E; Rader DJ
J Lipid Res; 2001 Jun; 42(6):943-50. PubMed ID: 11369802
[TBL] [Abstract][Full Text] [Related]
15. A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands.
Fisher C; Abdul-Aziz D; Blacklow SC
Biochemistry; 2004 Feb; 43(4):1037-44. PubMed ID: 14744149
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E3-mediated cellular uptake of reconstituted high-density lipoprotein bearing core 3, 10, or 17 nm hydrophobic gold nanoparticles.
Chuang ST; Shon YS; Narayanaswami V
Int J Nanomedicine; 2017; 12():8495-8510. PubMed ID: 29225464
[TBL] [Abstract][Full Text] [Related]
17. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):14-28. PubMed ID: 10685027
[TBL] [Abstract][Full Text] [Related]
18. Preparation of Lipid Nanodisks Containing Apolipoprotein E-Derived Synthetic Peptides for Biocompatible Delivery Vehicles Targeting Low-Density Lipoprotein Receptor.
Tanaka M; Hasegawa M; Yoshimoto N; Hoshikawa K; Mukai T
Biol Pharm Bull; 2019; 42(8):1376-1383. PubMed ID: 31366872
[TBL] [Abstract][Full Text] [Related]
19. Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia.
Blum CB; Deckelbaum RJ; Witte LD; Tall AR; Cornicelli J
J Clin Invest; 1982 Dec; 70(6):1157-69. PubMed ID: 6294137
[TBL] [Abstract][Full Text] [Related]
20. Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.
Lek MT; Cruz S; Ibe NU; Beck WHJ; Bielicki JK; Weers PMM; Narayanaswami V
PLoS One; 2017; 12(6):e0178346. PubMed ID: 28644829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
